Research article · 17 May 2022
Research articlePublished 3 Jan 2024
Analysis of Drug Formulary Exclusions from the Patient's Perspective: 2023 Update
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: Pharmacy Benefit Management companies (PBMs) often determine medication reimbursement, out of pocket costs, and access through formularies. Formularies were initially intended to ensure the use of cost-effective medication. Today, formularies are designed to maximize concessions (i.e., rebates, discounts, or fees) to PBMs from the biopharmaceutical industry. Formulary exclusions enhance the ability to drive profits through rebate contracting for PBMs. Our 2022 research analyzed whether formulary exclusions benefit patients medically or economically. This update provides an analysis of exclusions based on the 2023 Express Scripts (ESI) national formulary. Methods: We analyzed ESI’s 2023 national preferred formulary exclusions. ESI is the second-largest PBM in the U.S. and makes its national preferred formulary exclusions list publicly available. We categorized substitutions as equivalent (same active agent used) vs. therapeutic (different active agent). From a patient perspective, we evaluated each exclusion by potential clinical or economic outcomes and compared it to the results from the 2022 analysis. Results: More than half (57.4%) of the formulary exclusions had questionable economic or medical benefits or both for patients. The results demonstrate a 9% increase in questionable patient benefits compared with 48.4% in 2022. Conclusion: Because patient co-pays and deductibles are based on retail prices, some formulary exclusions force patients to pay substantially more for a preferred drug or use a medication with questionable medical benefits for their condition. Exclusions also force prescribers to choose treatments that may have adverse financial or medical outcomes for their patients. The pre-print version of this work is available on medRxiv: https://doi.org/10.1101/2023.11.01.23297921 .
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Case report · 29 Jan 2021
A Heavily Treated HIV-1 Infected Patient with Multiclass Drug Resistance: A Case Report and Review of Management Challenges in Settings with a Limited Formulary
Conference abstract · 19 Dec 2014
Evaluation of bacterial resistance pattern among thalassemia patients for updating hospital drug formulary
Other · 13 Jul 2016
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Research article · 25 Jan 2021
Updating of current AH & RC Hospital Formulary from 2016 to 2019
More from this journal
The newest in Health Science Journal.
Editorial · 31 Dec 2025
Energy-Boosting Nutrition: Fueling the Body for Optimal Performance and Vitality
Editorial · 31 Dec 2025
Digestive Balance: Maintaining a Healthy Gut for Optimal Digestion and Well-being
Editorial · 31 Dec 2025
Prebiotics: Exploring the Role of Dietary Components in Supporting Gut Health and Overall Wellness
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalHealth Science Journal
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Sara Chea”
- BylineArticles whose byline prints “Anne M. Sydor”
- BylineArticles whose byline prints “Robert Popovian”

